A Novel D-peptide modulates DCLK1 Gelsolin interactions, reducing PDAC tumor growth

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Pancreatic ductal adenocarcinoma (PDAC) progression is linked to inflammation and Doublecortin-like kinase 1 (DCLK1) overexpression.
• DCLK1 isoform 4, lacking kinase domains but possessing a unique extracellular domain (ECD), is crucial for tumor advancement.

Purpose of the Study:

• To investigate the role of DCLK1 isoform 4 in PDAC.
• To identify and characterize novel therapeutic agents targeting DCLK1 isoform 4's ECD.

Main Methods:

• In silico modeling and binding assays to analyze DCLK1 isoform 4 interactions.
• In vitro proliferation assays and in vivo xenograft models to evaluate D-peptide efficacy.
• Identification of D-peptides targeting the DCLK1 isoform 4 ECD.

Main Results:

• Novel D-peptides selectively target the DCLK1 isoform 4 ECD.
• D-peptides significantly suppressed PDAC cell proliferation and tumor growth in xenograft models without inducing cell death.
• DCLK1 isoform 4 interacts with plasma gelsolin (pGSN), and D-peptides modulate this interaction.

Conclusions:

• DCLK1's non-kinase functions, particularly via isoform 4, represent a viable therapeutic target in PDAC.
• D-peptides offer a novel strategy for precision treatment by inhibiting DCLK1-mediated tumor progression.
• Targeting DCLK1 isoform 4 interactions holds promise for improving patient outcomes in PDAC.